Drugs / RSVPreF3 OA vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07220109 | Oct 2025 → Sep 2026 expected | respiratory syncytial virus infectious disease | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06534892 | Aug 2024 → Sep 2026 expected | respiratory syncytial virus infectious disease | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05568797 | Oct 2022 → Feb 2023 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSVPreF3 OA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06534892 ↗ |
| Modality | Vaccine | “RSVPreF3 OA investigational vaccine” NCT05568797 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05568797 ↗ |